| 7.18 0 (0%) | 07-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.43 | 1-year : | 9.84 |
| Resists | First : | 7.21 | Second : | 8.43 |
| Pivot price | 6.55  |
|||
| Supports | First : | 5.27 |
Second : | 4.07 |
| MAs | MA(5) : | 7.17 | MA(20) : | 6.18 |
| MA(100) : | 4.49 |
MA(250) : | 4.44 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 98.2 |
D(3) : | 98.1 |
| RSI | RSI(14): 73.7 | |||
| 52-week | High : | 7.21 | Low : | 3.26 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ATAI ] has closed below upper band by 32.4%. Bollinger Bands are 160.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.21 - 7.24 | 7.24 - 7.27 |
| Low: | 7.06 - 7.11 | 7.11 - 7.15 |
| Close: | 7.11 - 7.19 | 7.19 - 7.25 |
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.
Tue, 28 Jul 2026
ATAI Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of AtaiBeckley to Eli Lilly - True North Radio Network
Mon, 27 Jul 2026
BlackRock (ATAI holder) reports 24.99M ATAIBECKLEY shares, a 6.8% position - Stock Titan
Fri, 17 Jul 2026
Eli Lilly to Buy Psychedelic Firm AtaiBeckley for Initial $2.8 Billion - wsj.com
Thu, 16 Jul 2026
Lilly to acquire AtaiBeckley for $2.8 billion upfront - Investing.com
Thu, 16 Jul 2026
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal - Reuters
Thu, 16 Jul 2026
Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 370 (M) |
| Held by Insiders | 3.0591e+008 (%) |
| Held by Institutions | 2.3 (%) |
| Shares Short | 23,550 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.219e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 239.1 % |
| Return on Equity (ttm) | -33.4 % |
| Qtrly Rev. Growth | 3.49e+006 % |
| Gross Profit (p.s.) | -24.65 |
| Sales Per Share | -240.77 |
| EBITDA (p.s.) | -3.47834e+007 |
| Qtrly Earnings Growth | -2.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -106 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 20.87 |
| Dividend | 0 |
| Forward Dividend | 3.779e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|